2. Academic Validation
  3. Mesenchymal Stem Cell Membrane-Camouflaged Liposomes for Biomimetic Delivery of Cyclosporine A for Hepatic Ischemia-Reperfusion Injury Prevention

Mesenchymal Stem Cell Membrane-Camouflaged Liposomes for Biomimetic Delivery of Cyclosporine A for Hepatic Ischemia-Reperfusion Injury Prevention

  • Adv Sci (Weinh). 2024 Jun 20:e2404171. doi: 10.1002/advs.202404171.
Haitian Chen 1 2,  Wen Yin 3 4,  Kang Yao 1 2,  Jinliang Liang 2 5,  Jianye Cai 1,  Xin Sui 2 6,  Xuegang Zhao 2 6,  Jiebin Zhang 1,  Jiaqi Xiao 1,  Rong Li 2 5,  Qiuli Liu 7,  Jia Yao 1,  Guohua You 6,  Yasong Liu 1,  Chenhao Jiang 1,  Xiaotong Qiu 2,  Tingting Wang 2,  Qiang You 2,  Yingcai Zhang 8,  Mo Yang 4,  Jun Zheng 1,  Zong Dai 3,  Yang Yang 1 2
Affiliations

Affiliations

  • 1 Department of Hepatic Surgery and Liver Transplantation Center of The Third Affiliated Hospital, Organ Transplantation Institute, Sun Yat-sen University, Organ Transplantation Research Center of Guangdong Province, Guangdong Province Engineering Laboratory for Transplantation Medicine, Guangzhou, 510630, China.
  • 2 Guangdong Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510630, China.
  • 3 School of Biomedical Engineering, Shenzhen Campus of Sun Yat-sen University, Shenzhen, 518107, China.
  • 4 Department of Biomedical Engineering, The Hong Kong Polytechnic University, Hong Kong, 999077, China.
  • 5 Guangdong province engineering laboratory for transplantation medicine, Guangzhou, China.
  • 6 Surgical ICU, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510630, China.
  • 7 The Biotherapy Center, the Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510630, China.
  • 8 Department of Hepatobiliary Surgery, People's Hospital of Xinjiang Uyghur Autonomous Region, Urumqi, 830001, China.
PMID: 39031840 DOI: 10.1002/advs.202404171
Abstract

Hepatic ischemia-reperfusion injury (HIRI) is a prevalent issue during liver resection and transplantation, with currently no cure or FDA-approved therapy. A promising drug, Cyclosporin A (CsA), ameliorates HIRI by maintaining mitochondrial homeostasis but has systemic side effects due to its low bioavailability and high dosage requirements. This study introduces a biomimetic CsA delivery system that directly targets hepatic lesions using mesenchymal stem cell (MSC) membrane-camouflaged liposomes. These hybrid nanovesicles (NVs), leveraging MSC-derived proteins, demonstrate efficient inflammatory chemotaxis, transendothelial migration, and drug-loading capacity. In a HIRI mouse model, the biomimetic NVs accumulated at liver injury sites entered hepatocytes, and significantly reduced liver damage and restore function using only one-tenth of the CsA dose typically required. Proteomic analysis verifies the protection mechanism, which includes Reactive Oxygen Species inhibition, preservation of mitochondrial integrity, and reduced cellular Apoptosis, suggesting potential for this biomimetic strategy in HIRI intervention.

Keywords

biomimetic delivery; cyclosporine A; ischemia‐reperfusion injury; mesenchymal stem cell.

Figures
Products
Inhibitors & Agonists
Other Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z